Curriculum Vitae. B.Sc, Biomedical Science, The University of Technology Sydney, Graduated with distinction and a GPA of 3.

Transcription

1 Curriculum Vitae Dr. Zaynab Al-Eisawi Mobile: / Nationality: Australian/Jordanian Education: Ph.D., Biomedical Science, The University of Sydney, Concentrations: Cancer cell molecular biology, Platinum anti-cancer drugs, Ovarian cancer Title: Combination of platinum drugs and Bortezomib and changes in nature of administration in ovarian tumour models M.Phil., Biomedical Science, The University of Sydney, B.Sc, Biomedical Science, The University of Technology Sydney, Graduated with distinction and a GPA of 3.6 Principles and Practice of University Teaching and Learning, The University of Sydney, A focus on student engagement strategies. Experience: Academic Sep current Position: Lecturer The Hashemite University, Jordan Course: Pathology, medical microbiology and hematology for undergraduate students. Academic Oct July 2015 Position: Assistant Professor The University of Sydney and Australian Catholic University, Australia Course: Human Anatomy and Physiology, Biology, Cell Biology for both undergraduate and postgraduate students. Academic Jan Sep Position: Lecturer The University of Sydney, Australia Course: Human Anatomy and Physiology, Biology, Cell Biology, Neuroscience. Research Collaboration Aug current Position: Scientific consultant and editor Botanical drugs company PANAXEA, Australia Triple Negative Breast Cancer treatment using phytochemicals Post-doctoral Fellow Jan The University of Sydney, Australia Molecular Pharmacology and Pathology Program lead by Prof Des Richardson Focus: Chelators as novel potent anticancer drugs

2 Publications: Zaynab Al-Eisawi, Christian Stefani, Patric J. Jansson, Akanksha Arvind, Philip C. Sharpe, Maram T. Basha, George M. Iskander, Naresh Kumar, Zaklina Kovacevic, Darius J. R. Lane, Sumit Sahni, Paul V. Bernhardt, Des R. Richardson, and Danuta S. Kalinowski. Novel Mechanism of Cytotoxicity for the Selective Selenosemicarbazone, 2-Acetylpyridine 4,4- Dimethyl-3-selenosemicarbazone (Ap44mSe): Lysosomal Membrane Permeabilization. Journal of Medicinal Chemistry, 2016, 59 (1), pp Christian Stefani, Zaynab Al-Eisawi, Patric J. Jansson, Des R. Richardson and Danuta S. Kalinowski. Identification of Differential Anti-Neoplastic Activity of Copper Bis(Thiosemicarbazones) that is Mediated by Intracellular Reactive Oxygen Species Generation and Lysosomal Membrane Permeabilization. Journal of Inorganic Biochemistry, 152, November 2015, pp Daniel Weber, Mixia Zhang, Pengwei Zhuang, Yanjun Zhang, Janelle Wheat, Geoffrey Currie and Zaynab Al-Eisawi. The efficacy of betulinic acid in triple-negative breast cancer. SAGE open Medicine, 2014, doi: / Zaynab Al-Eisawi, Philip Beale, Charles Chan, Jun Qing Yu and Fazlul Huq. Combinations of Platinum Drugs with Bortezomib in Ovarian cancer Cell Lines. Proceeding of 18th World Congress on COGI - Vienna, Austria, October 24-27, Monduzzi Editoriale Zaynab Al-Eisawi, Philip Beale, Charles Chan, Jun Qing Yu and Fazlul Huq. Carboplatin and oxaliplatin in sequenced combination with bortezomib in ovarian tumour models. Journal of Ovarian Research, 2013, 6:78. Zaynab Al-Eisawi, Philip Beale, Charles Chan, Jun Qing Yu and Fazlul Huq. Modulation of Cisplatin Cytotoxicity due to its combination with Bortezomib and the nature of its administration. Anticancer Research, 2011, 31, pp Fazlul Huq and Zaynab Al-Eisawi. Molecular modelling analysis of the metabolism of bortezomib. International Journal of Pure and Applied Chemistry, 2011, 6: (3). Zaynab Al-Eisawi, Philip Beale, Charles Chan, Jun Qing Yu and Fazlul Huq. Combinations between platinum drugs and bortezomib and changes in nature of administration in ovarian tumour models. 2013, University of Sydney theses.

3 Conference presentations: The fourth Sydney Cancer Conference 2014 (26-28 November, 2014) organizing committee member. Al-Eisawi Z, Beale P, Chan C, Yu J Q, Huq F. Combinations of Platinum Drugs with Bortezomib in Ovarian cancer Cell Lines October The 18 World Congress on COGI Vienna, Austria. Al-Eisawi Z, Beale P, Chan C, Yu J Q, Huq F. The sequenced combinations of platinum drugs with bortezomib in ovarian tumour models October The 18 International Meeting of the European Society of Gynaecological Oncology (ESGO 2013) Liverpool, England. Al-Eisawi Z, Beale P, Chan C, Yu J Q, Huq F. Aiming to maximise antitumour activity of platinum drugs in ovarian tumour models October The 11 International Symposium on Platinum Coordination Compound in Cancer Chemotherapy, Verona Italy. Al-Eisawi Z, Beale P, Chan C, Yu J Q, Huq F. Synergism between cisplatin and Bortezomib in ovarian cancer cells February rd International Conference on Drug Discovery and Therapy, Dubai, UAE. Al-Eisawi Z, Beale P, Chan C, Yu J Q, Huq F. Maximising the cell kill due to platinum drugs in the human ovarian tumour models February, th International Conference on Drug Discovery and Therapy, Dubai, UAE. Al-Eisawi Z, Beale P, Chan C, Yu J Q, Huq F. Maximising the effect of platinum drugs in ovarian tumour models September The Sydney Cancer Conference. Al-Eisawi Z, Beale P, Chan C, Yu J Q, Huq F. Enhancement of cisplatin action due to combination with bortezomib in ovarian in vitro tumour models. 3 December, Postgraduate Cancer Research Symposium, The University of Sydney. Al-Eisawi Z, Beale P, Chan C, Yu J Q, Huq F. Cisplatin and Bortezomib combination in ovarian cancer cells November. Bosch Institute Young Investigators Symposium, The University of Sydney. Al-Eisawi Z, Beale P, Chan C, Yu J Q, Huq F. New hope in ovarian cancer. Three Minute Thesis Competition, The University of Sydney. Finalist. 7 September Al-Eisawi Z, Beale P, Chan C, Yu J Q, Huq F. Maximising the Effect of Platinum Drugs in Ovarian Cancer. 29 of November The Cancer Research Network Postgraduate Symposium, The University of Sydney. Awarded the most outstanding platinum based treatments award. Al-Eisawi Z, Beale P, Chan C, Yu J Q, Huq F. Ovarian Cancer: New Hope in Current Therapy. 1 December The Bosch institute Symposium, The University of Sydney. Al-Eisawi Z, Beale P, Chan C, Yu J Q, Huq F. Platinum drugs applied to ovarian tumour models. 26 of July Bosch Annual Scientific Meeting, The University of Sydney.

4 Discipline presentations: Al-Eisawi Z. Bortezomib and Platinums in combination in ovarian cancer. Discipline of Biomedical Science research seminar. September Al-Eisawi Z. Enhanced Delivery of Cisplatin to Intraperitoneal Ovarian Carcinomas Mediated by the Effects of Bortezomib on the Human Copper Transporter 1. Cancer Research Group Journal Club. 14 April Al-Eisawi Z. Primary ovarian cancer cells are sensitive to the pro-apoptotic effects of proteasome inhibitors. Cancer Research Group Journal Club. 2 September Al-Eisawi Z. Modulation of Cisplatin Cytotoxicity due to its Combination with Bortezomib and Nature of its Administration. Discipline of Biomedical Science research seminar. 19 April Al-Eisawi Z. Enhanced g-glutamylcysteine Synthetase Activity Decreases Drug-Induced Oxidative Stress Levels and Cytotoxicity. Cancer Research Group Journal Club. 12 May Al-Eisawi Z. Relevance of drug uptake and efflux for cisplatin sensitivity of tumour cells. Cancer Research Group Journal Club. 25 August Al-Eisawi Z. The kinetics and cytotoxicity of cisplatin and its monohydrated complex. Cancer Research Group Journal Club. 29 March Al-Eisawi Z, Beale P, Chan C, Yu J Q, Huq F. Platinum drugs in ovarian tumour models. August Final thesis presentation, The University of Sydney. Grants and Fellowships: The Discipline of Biomedical Science PhD Research Scholarship Postgraduate research scholarship scheme (PRSS) 2010 Postgraduate research scholarship scheme (PRSS) 2011 Postgraduate research scholarship scheme (PRSS) 2012 Awards and Honours: Most Outstanding Platinum Based Treatments Presentation Award Cancer Research Institute M. Y. Ali Prize in Anatomical pathology Member of the Australian Society for Medical Research (ASMR) Member of the Golden Key International Honour Society (only offered to the top 5% achievers of the university) Sydney Cancer Conference 2014 organising committee member Technical Competence and Skills: Technical competence in the use of biochemical instrumentation and molecular biology techniques including cell culture, transfection, drug synthesis, radiolabelling, instrumental analyses, proteomics, western blotting, RT-PCR, immunofluorescence, flow cytometry, live cell imaging and many more molecular biology techniques.

5 References: Name: A/Prof Fazlul Huq Position: Associate Professor of cancer Phone: fazlul.huq@sydney.edu.au Name: A/Prof Philip Beale Position: Clinical Oncologist Phone: Philip.Beale@sswahs.nsw.gov.au Name: A/Prof Charles Chan Position: Clinical Pathologist Phone: Charles.Chan3@sswahs.nsw.gov.au Name: Prof Des Richardson Position: Professor of cancer cell biology Phone: d.richardson@sydney.edu.au Name: Dr Danuta Kalinowski Position: Medicinal Chemist Phone: danuta.kalinowski@sydney.edu.au